Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial

BACKGROUND: Neoadjuvant systemic treatment (NST) leads to pathologic complete response (pCR) in 10–89% of breast cancer patients depending on subtype. The added value of surgery is uncertain in patients who reach pCR; however, current imaging and biopsy techniques aiming to predict pCR are not accur...

Descripción completa

Detalles Bibliográficos
Autores principales: van Hemert, Annemiek K. E., van Duijnhoven, Frederieke H., van Loevezijn, Ariane A., Loo, Claudette E., Wiersma, Terry, Groen, Emilie J., Peeters, Marie-Jeanne T. F. D. Vrancken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Breast Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319687/
https://www.ncbi.nlm.nih.gov/pubmed/37071235
http://dx.doi.org/10.1245/s10434-023-13476-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319687/
https://www.ncbi.nlm.nih.gov/pubmed/37071235
http://dx.doi.org/10.1245/s10434-023-13476-6

Ejemplares similares